for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alector Inc

ALEC.OQ

Latest Trade

9.71USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

9.24

 - 

35.93

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.71
Open
--
Volume
--
3M AVG Volume
22.65
Today's High
--
Today's Low
--
52 Week High
35.93
52 Week Low
9.24
Shares Out (MIL)
79.26
Market Cap (MIL)
777.56
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Alector Inc Earnings Release

Latest Developments

More

Alector Reports Second Quarter 2020 Financial Results And Provides Corporate Update

Alector Plans To Present Additional Phase 2 Data Highlighting Clinical & Biomarker Endpoints In Future

Alector Says Orbimed Advisors Cuts Share Stake In Co To 3.5% From 7.0%

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alector Inc

Alector, Inc. is a clinical-stage biopharmaceutical company focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL101, Al002 and AL003. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).

Industry

Biotechnology & Drugs

Contact Info

151 Oyster Point Blvd Ste 300

SOUTH SAN FRANCISCO, CA

94080-1841

United States

+1.415.2315660

https://alector.com

Executive Leadership

Tillman U. Gerngross

Chairman of the Board, Co-Founder

Shehnaaz Suliman

President, Chief Operating Officer

Arnon Rosenthal

Chief Executive Officer, Co-Founder, Director

Calvin Yu

Vice President - Finance

Robert Siang-Shu King

Chief Development Officer

Key Stats

1.56 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-4.620

2019

-1.710

2020(E)

-2.266
Price To Earnings (TTM)
--
Price To Sales (TTM)
40.84
Price To Book (MRQ)
2.19
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-32.22
Return on Equity (TTM)
-28.14

Latest News

Latest News

IFR US ECM Calendar

Alector (US, biotech) – $208.9m FO. 8.35m shares (100% prim) at $25.00 versus $25.94 last sale and $25.34 at launch. MS, GS, BOFA, COWN. Upsized from 5.1m on 1/29 to 7.0m shares.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up